Please login to the form below

Not currently logged in
Email:
Password:

Teva completes Cephalon purchase

Teva Pharmaceutical has acquired US-based biopharmaceutical company Cephalon for about $6.8bn following approval from the European Union

Teva Pharmaceutical has acquired US-based biopharmaceutical company Cephalon for about $6.8bn following approval from the European Union (EU).

The EU had demanded that Teva sell off its generic version of Cephalon's narcolepsy drug, Provigil (modafinil), to enable another company to own a competitor product.

Cephalon is now a wholly owned subsidiary of Teva, with Cephalon to receive $81.50 per share of common stock.

Teva said the combined company is to have a presence in over 60 countries. As individual companies, the combined revenue of Teva and Cephalon for the period July 2010 to June 2011 was around $20bn.

Shlomo Yanai, president and CEO of Teva, said the purchase was part of the Israel-based company's attempt to build its branded pharmaceuticals business through diversification and expansion of its product portfolio and pipeline.

17th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics